Supply Chain Archives
06/04/2025
Engineering for Impact: A Conversation with Mike Dybicz on the HV3 and Safepak Systems
When it comes to cell and gene therapy (CGT) logistics, innovation is about more than improving efficiency, it’s about safeguarding a patient’s only chance at treatment. We sat down with Mike Dybicz, Senior Vice President & Chief Product Development Officer, to discuss how Cryoport Systems is reshaping the future of CGT logistics with innovative products such as Cryoport Express® Cryogenic HV3 Shipping System and Safepak® System 1800, designed specifically to reduce risk, increase reliability, and ultimately improve patient outcomes.
04/29/2025
Optimizing Cryopreservation for Leukapheresis: Advancing Cell and Gene Therapy Supply Chains
The supply chain for fresh leukapheresis is one of the most complex logistical challenges in cell and gene therapy (CGT). As a critical starting material, leukapheresis must be collected from donors, processed, and transported within a limited time window. These challenges increase variability and risk, ultimately impacting the success of advanced therapies. Alexandre Michaux, Process Development & MSAT Manager at IntegriCell™ , recently presented his work on the development of an automated cryopreservation process for leukapheresis in a Poster Presentation at Advanced Therapies Congress in London.
04/22/2025
Advancing Standardization in Cell and Gene Therapy Supply Chains
The future of cell and gene therapy depends not only on scientific advancements but also on the efficiency and reliability of its supply chain. In a recent panel discussion at Advanced Therapies Congress in London, industry experts explored the critical need for standardization, the challenges in achieving it, and the opportunities to improve logistics, manufacturing, and delivery systems.
04/18/2025
Transforming Patient Access to CGT: Q&A with Aruna Mor
Aruna Mor, Chief Commercial Officer at Cryoport Systems, recently delivered a powerful keynote at Advanced Therapies Congress in London, shedding light on the complexities of patient access and the critical steps needed to overcome these barriers. We sat down with her to delve deeper into some of the key themes of her keynote, exploring the intersection of science, logistics, supply chain, regulation, and collaboration that will determine the future of Cell and Gene Therapy (CGT).
04/14/2025
Enabling the Outcome Through Enhancing Patient Accessibility
Cell and Gene Therapy (CGT) has emerged as one of the most transformative areas in modern medicine, shaping the future of healthcare and changing the face of next-generation therapeutic approaches. Yet, despite the continued scientific progress, a critical challenge persists in ensuring these therapies are accessible to the patients who need them most. This challenge was the focus of the keynote address at the Advanced Therapies Congress in London, delivered by Aruna Mor, Chief Commercial Officer at Cryoport Systems, where she spoke about to the state of patient access within the field of advanced therapeutics.
02/12/2025
Ensuring Patient Impact in Advanced Therapy Logistics: A Conversation with Cryoport Systems’ Experts
The logistics behind advanced therapies aren’t just about moving shipments from point A to point B, they’re about protecting the integrity of life-saving treatments and ensuring that patients receive them without compromise. Following their discussion at Advanced Therapies Week 2025, we sat down with Aruna Mor, Chief Commercial Officer, and Mike Dybicz, Senior Vice President & Chief Product Development Officer, to dive deeper into how Cryoport Systems prioritizes patient impact at every step of the supply chain.
02/12/2025
Advancing Cell and Gene Therapy on International Childhood Cancer Day
Every year on February 15th, International Childhood Cancer Day (ICCD) serves as a global platform to raise awareness about childhood cancer, advocate for improved access to care, and highlight the need for continued research and innovation. Pediatric cancer remains one of the leading causes of death among children worldwide, with approximately 400,000 new cases diagnosed each year.
02/06/2025
The Patient Ferris Wheel: Centering the Patient in the CGT Supply Chain
In a recent interview at ATW, Cryoport Systems' leadership discussed how securing the future of medicine starts with minimizing risk and maximizing patient impact. Their conversation, The Patient Ferris Wheel – Centering the Patient in CGT Supply Chain, explored how Cryoport Systems is driving innovation in shipping systems designed specifically for advanced therapies.
02/04/2025
